4 • Sep–Dec 2023 • Vol LXII • No. 5 An excerpt of the clinical study conducted by Kumar PKM et al published in the journal Medicine Update is featured here. Research at Himalaya Diabecon® in the Management of Type 2 Diabetes Mellitus Diabecon® (TABLET, DS TABLET) The beacon of hope for diabetics Diabecon, an Ayurvedic proprietary formulation, is recommended for the management of diabetes mellitus and associated micro- and macrovascular complications. In newly detected type 2 diabetes mellitus, Diabecon as a monotherapy significantly reduces FPG, PPG, and HbA1c levels. As an adjuvant to insulin or other oral hypoglycemic agents, Diabecon helps in reducing their dosage and prevents development of tolerance. A clinical study was conducted to evaluate the safety and efficacy of Diabecon in controlling the blood sugar and glycosylated hemoglobin (HbA1c) levels and lipid profile in patients with non–insulin-dependent diabetes mellitus (NIDDM). The study enrolled 30 nonobese patients (aged > 30 y; both men and women) with NIDDM. The study groups comprised 15 patients newly diagnosed with persistent hyperglycemia, and 15 patients with diabetes who were already on sulfonylurea therapy. Patients with severe cardiovascular disorders, hypertension, and pregnant women were excluded from this study. The patients’ medical history was recorded, and baseline clinical and biochemical examinations were performed. The patients in both the groups (newly diagnosed and adjuvant therapy) were prescribed Diabecon at a dosage of 2 tablets, TID, for 6 months. FBS and PPBS levels were noted every 15 days. Plasma lipid profile and HbA1c and insulin levels were assessed at the baseline and after 3 and 6 months of Diabecon treatment. At each fortnightly follow-up, the patients were examined for side effects. Statistical analysis was performed using MANOVA and paired t test. The results showed that the treatment with Diabecon significantly reduced the FBS and PPBS levels and HbA1c level in both the patient groups. In patients on sulfonylurea therapy, administration of Diabecon brought about better glycemic control, thereby delaying the need for initiation of insulin therapy. A reduction in the lipid levels was also observed in both the groups. No side effects were reported or observed during the study. Thus, the results demonstrate the safety and efficacy of Diabecon tablet in controlling blood sugar and HbA1c levels and lipid profile in patients with NIDDM. A clinical study was conducted to evaluate the efficacy of Diabecon in the management of type 2 diabetes mellitus (T2DM). The study enrolled 15 patients (aged 30–60 y; both men and women) with T2DM. Patients on oral hypoglycemic drugs were asked to discontinue medication for 2 weeks prior to this study. On day 1, the baseline insulin and fasting blood sugar (FBS) levels were measured, and 1 g tolbutamide was given to the patients. Insulin and postprandial blood sugar (PPBS) levels were measured at the first, second, and third hour after the meal. On day 2, the patients were given a standard test meal (460 kcal) and insulin and PPBS levels were measured again at the first, second, and third hours after the meal. Diabecon was given at a dosage of 2 tablets, BID, and the investigations were repeated for 3 months. Tolbutamide was given on day 1 and the test meal on day. Further, Diabecon was continued everyday for 3 months. Statistical analysis was performed using ANOVA. The treatment with Diabecon resulted in a decrease in the FBS and PPBS levels. Overall, there was a significant decrease in the blood sugar level (Figure) and increase in the serum insulin level by the end of the study. Thus, the results confirm the clinical efficacy of Diabecon in the management of T2DM. Clinical Evidence 2 Clinical Evidence 1 An excerpt of the clinical study conducted by Seshaiah V et al published in the journal The Indian Practitioner is featured here. Figure. Blood Sugar Level Before and After the Treatment With Diabecon FBS, fasting blood sugar. Time Before Treatment After Treatment 160.8 156.4 181.9 190.3 187.6 220.4 256.6 256.9 300 0 50 100 150 200 200 At 2 h Blood Sugar, mg/dL At 3 h FBS At 1 h
RkJQdWJsaXNoZXIy MjAwNDg=